Headlands Research Summit Portland Marked 50th Anniversary
The Portland facility celebrated five decades of conducting clinical research on memory health and neurological conditions.
Updated on Oct. 12, 2026 in Alzheimer’s
Headlands Research Summit Portland observed its 50th anniversary in 2026, marking five decades of operation in the city. The facility has played a significant role in clinical research across various therapeutic areas, including central nervous system conditions and memory health.
Why it matters
The milestone highlights the facility's long-standing contribution to advancing medical treatments for complex health conditions. Its work has been instrumental in supporting the development of pharmaceutical therapies over the last half-century.
Since 1993, the facility has contributed to research supporting every FDA-approved class of Alzheimer's disease medication. Researchers have conducted 75 clinical trials specifically for Alzheimer's and 150 for broader nervous system disorders.
The players
Headlands Research Summit Portland
This is a clinical research facility in Portland, Oregon, that focuses on testing treatments for mental health and central nervous system disorders.
Dr. Scott Losk
A physician who has practiced at the facility since 1990 and served as a principal investigator on more than 75 clinical trials for Alzheimer's disease.
The details
The Portland facility specializes in clinical trials for mental health, vaccines, diabetes, and obesity while maintaining a dedicated Memory Health Centre for dementia patients. By partnering with pharmaceutical companies, the site facilitates the rigorous testing required for new medical treatments.
Timeline
Headlands Research Summit Portland was founded in 1976.
Dr. Scott Losk began practicing at the facility in 1990.
Facility research supported the first Alzheimer's drug class starting in 1993.
The facility celebrated its 50th anniversary in 2026.
Health Landscape
This milestone reflects a broader trend of private research sites acting as cornerstones for the development of the FDA-approved class of Alzheimer's disease medications. The facility demonstrates how sustained, multi-decade clinical investment bridges the gap between laboratory discovery and patient-facing treatment.
Local residents with memory-related conditions benefit from the facility's long-standing operation of a Memory Health Centre, which provides access to ongoing clinical studies. This proximity to established research trials offers patients in the area increased opportunities to participate in the evaluation of emerging Alzheimer's treatments.
The takeaway
The longevity of local research institutions ensures that patients have consistent access to the most recent medical advancements in their own community. Engaging with clinical trial centers allows individuals to play an active role in the evolution of future therapies for dementia.
Further reading
Learn more about the latest research and support resources at the Portland Alzheimer’s center.
Source note: This article includes information reported by Scientist Live.
